Regencell Bioscience Holdings Limited (NASDAQ:RGC - Get Free Report) rose 8.7% during trading on Tuesday. The company traded as high as $7.06 and last traded at $7.3490. Approximately 101,532 shares were traded during mid-day trading, a decline of 66% from the average daily volume of 299,003 shares. The stock had previously closed at $6.76.
Wall Street Analysts Forecast Growth
Several brokerages recently weighed in on RGC. Weiss Ratings restated a "sell (e+)" rating on shares of Regencell Bioscience in a research report on Monday, September 21st. Wall Street Zen lowered Regencell Bioscience from a "hold" rating to a "sell" rating in a research note on Saturday, July 18th. One analyst has rated the stock with a Sell rating. According to MarketBeat.com, the stock has an average rating of "Sell".
Get Our Latest Report on Regencell Bioscience
Regencell Bioscience Stock Performance
The company has a 50 day moving average of $6.70 and a two-hundred day moving average of $17.98.
Regencell Bioscience (NASDAQ:RGC - Get Free Report) last announced its quarterly earnings data on Wednesday, October 7th. The company reported ($0.01) EPS for the quarter.
Institutional Trading of Regencell Bioscience
An institutional investor recently bought a new stake in Regencell Bioscience stock. Amundi purchased a new stake in Regencell Bioscience Holdings Limited (NASDAQ:RGC - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 8,595 shares of the company's stock, valued at approximately $219,000. 0.13% of the stock is currently owned by institutional investors.
About Regencell Bioscience
(
Get Free Report)
Regencell Bioscience Holdings Limited is a Hong Kong-based biotechnology company focused on developing traditional Chinese medicine (TCM) formulations for neurological and neurocognitive disorders. Its research has primarily targeted attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD), conditions for which the company is exploring TCM-based therapeutic approaches.
The company's development activities center on proprietary herbal formulations and related treatment protocols.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Regencell Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regencell Bioscience wasn't on the list.
While Regencell Bioscience currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.
